TY - JOUR
T1 - Simultaneous administration of live, enteric-coated adenovirus types 4, 7, and 21 vaccines
T2 - Safety and immunogenicity
AU - Takafuji, Ernest T.
AU - Gaydos, Joel C.
AU - Alien, Richard G.
AU - Top, Franklin H.
N1 - Funding Information:
Received for publication May 15, 1978, and in revised form February 8, 1979. We thank the personnel of the U.S. Air Force Military Training Center and Wilford Hall Medical Center, Lackland Air Force Base, Texas, for their support and cooperation. Professional assistance was provided by Dr. Vicente Martinez, Lackland Air Force Base; Drs. George D. Lathrop and Louis Blouse, Jr., Brooks Air Force Base, Texas; and Drs. Richard A. Hodder, Douglas B. Tang, and Herbert E. Segal, The Walter Reed Army Institute of Research, Washington, D.C. We thank M. C. Callahan, L. C. Evans, D. A. Leach, H. G. Cannon, B. H. Robinson, J. R. Putnak, K. V. Belleville, and V. Kelley for technical assistance. Please address requests for reprints to Dr. Joel C. Gaydos, Division of Preventive Medicine, The Walter Reed Army Institute of Research, Washington, D.C. 20012. ,.. Present address: U.S. Army Medical Department Activity, Fort Bragg, North Carolina. t Present address: U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland.
PY - 1979/7
Y1 - 1979/7
N2 - The safety of and the immune response to simultaneous administration of live, enteric-coated adenovirus type 4 (ADV-4), type 7 (ADV-7), and type 21 (ADV-21) vaccines were studied. Volunteers (476 men), randomly assigned to four study groups, received three vaccines (ADV-4, ADV-7, and ADV-21), two vaccines (ADV-4 and ADV-7), one vaccine (ADV-21), or no vaccine (placebo). Subjects were observed for three weeks, and no side effects due to vaccination occurred. The percentages of susceptible subjects (those entering the study with a neutralizing antibody titer of <1:2 to each vaccine virus received) who seroconverted to ADV-4 were similar in both groups that received ADV-4 vaccine (78% of 77 subjects and 74% of 76). However, in the group that received three vaccines, only 62% of 77 subjects seroconverted to ADV-7, compared with 79% of 76 in the group that received two vaccines (P < 0.05). Only 58% of 77 subjects in the three-vaccine group seroconverted to ADV-21, compared with 69% of 59 in the group that received one vaccine (P > 0.1).
AB - The safety of and the immune response to simultaneous administration of live, enteric-coated adenovirus type 4 (ADV-4), type 7 (ADV-7), and type 21 (ADV-21) vaccines were studied. Volunteers (476 men), randomly assigned to four study groups, received three vaccines (ADV-4, ADV-7, and ADV-21), two vaccines (ADV-4 and ADV-7), one vaccine (ADV-21), or no vaccine (placebo). Subjects were observed for three weeks, and no side effects due to vaccination occurred. The percentages of susceptible subjects (those entering the study with a neutralizing antibody titer of <1:2 to each vaccine virus received) who seroconverted to ADV-4 were similar in both groups that received ADV-4 vaccine (78% of 77 subjects and 74% of 76). However, in the group that received three vaccines, only 62% of 77 subjects seroconverted to ADV-7, compared with 79% of 76 in the group that received two vaccines (P < 0.05). Only 58% of 77 subjects in the three-vaccine group seroconverted to ADV-21, compared with 69% of 59 in the group that received one vaccine (P > 0.1).
UR - https://www.scopus.com/pages/publications/0018761973
U2 - 10.1093/infdis/140.1.48
DO - 10.1093/infdis/140.1.48
M3 - Article
C2 - 458200
AN - SCOPUS:0018761973
SN - 0022-1899
VL - 140
SP - 48
EP - 53
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 1
ER -